These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 476270)

  • 41. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma.
    O'Connor TP; Labandter HP; Hiles RW; Bodenham DC
    Br J Plast Surg; 1978 Oct; 31(4):317-22. PubMed ID: 361132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunologic effects of BCG in patients with malignant melanoma: specific evidence for stimulation of the 'secondary' immune response.
    Chess L; Bock GN; Ungaro PC; Buchholz DH; Mardiney MR
    J Natl Cancer Inst; 1973 Jul; 51(1):57-65. PubMed ID: 4720886
    [No Abstract]   [Full Text] [Related]  

  • 43. Intralesional immunotherapy of melanoma with BCG.
    Rosenberg SA; Rapp HJ
    Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Histologic changes in the human skin melanoma after intratumorous treatment with BCG.
    Svejda J; Mechl Z; Sopková B; Foukal T
    Neoplasma; 1979; 26(2):215-21. PubMed ID: 471128
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adjuvant immunotherapy for vulvar malignant melanoma.
    Wallach RC; Taub RN
    Mt Sinai J Med; 1979; 46(2):161-2. PubMed ID: 312443
    [No Abstract]   [Full Text] [Related]  

  • 46. Sequential examination of lymphocyte proliferative capacity in patients with malignant melanoma receiving BCG immunotherapy.
    Golub SH; Forsythe AB; Morton DL
    Int J Cancer; 1977 Jan; 19(1):18-26. PubMed ID: 137880
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BCG immunotherapy of malignant melanoma: summary of a seven-year experience.
    Morton DL; Eilber FR; Holmes EC; Hunt JS; Ketcham AS; Silverstein MJ; Sparks FC
    Ann Surg; 1974 Oct; 180(4):635-43. PubMed ID: 4412271
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Malignant melanoma metastatic to the bladder. Regression following intratumor injection of BCG vaccine.
    Silverstein MJ; DeKernion J; Morton DL
    JAMA; 1974 Aug; 229(6):688. PubMed ID: 4408302
    [No Abstract]   [Full Text] [Related]  

  • 49. Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan.
    Schwarz MA; Gutterman JU; Burgess MA; Heilbrun LK; Murphy WK; Bodey GP; Stone E; Turner-Chism V; Hersh EM
    Cancer; 1980 May; 45(10):2506-15. PubMed ID: 7378986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
    Kokoschka EM; Cerni C; Micksche M
    Oncology; 1977; 34(5):229-33. PubMed ID: 917456
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
    Coates AS; Peters M
    Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of oral BCG in the treatment or metastatic malignant melanoma.
    Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
    Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Common human melanoma membrane antigens detected by mixed hemadsorption microassay with serum from a patient undergoing immunotherapy with autologous tumor cells.
    Liao SK; Leong SP; Sutherland CM; Dent PB; Kwong PC; Krementz ET
    Cancer Res; 1978 Dec; 38(12):4395-400. PubMed ID: 82477
    [No Abstract]   [Full Text] [Related]  

  • 54. BCG immunotherapy in patients with malignant melanoma.
    Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
    Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Deutschmann KE; Peter HH; Schultheis W; Deicher H
    Tumori; 1977; 63(3):303-7. PubMed ID: 898298
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Letter: Ascites in malignant melanoma after oral BCG immunotherapy.
    Nutting MG; McPherson TA
    N Engl J Med; 1976 Aug; 295(7):395. PubMed ID: 934232
    [No Abstract]   [Full Text] [Related]  

  • 57. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection.
    McKhann CF; Hendrickson CG; Spitler LE; Gunnarsson A; Banerjee D; Nelson WR
    Cancer; 1975 Feb; 35(2):514-20. PubMed ID: 234291
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of systemic BCG therapy in advanced melanoma.
    El-Domeiri AA; Nika B; Hsia WC; Crispen R; Sabet TY; Gupta TK
    Arch Surg; 1977 Mar; 112(3):257-9. PubMed ID: 843215
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of BCG immunotherapy on alloantigen-induced blastogenesis and cytotoxicity of lymph node lymphocytes in patients with melanoma.
    Callery CD; Morton DL; Golub SH
    Surg Forum; 1979; 30():152-4. PubMed ID: 161421
    [No Abstract]   [Full Text] [Related]  

  • 60. Immunotherapy in patients with melanoma.
    Seiger HF; Shingleton WW; Metzgar RS; Buckley CE
    Ann Surg; 1973 Sep; 178(3):352-9. PubMed ID: 4269702
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.